In addition to greater relevance of PFKFB3-mediated glycolysis in other cell types in atherosclerosis, or off-target effects of reported inhibitors, other factors may explain the observed lack of effect of myeloid Pfkfb3 inhibition on atherosclerosis. The gene discussed is PFKFB3; the disease is atherosclerosis.